1 completed, 1 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Pierluigi Porcu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL) VK-2019 - Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed | Phase 1 | Recruiting | Pierluigi Porcu | 30 | 2026-08-21 | 2026-09-02 |
| Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma azacitidine, bortezomib, Correlative studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Pierluigi Porcu | 8 | 2010-05-01 | 2013-12-03 |
Epstein-Barr Virus Infections (1) · Immunoblastic Lymphadenopathy (1) · Infections (1) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Prolymphocytic (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Mycosis Fungoides (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Sezary Syndrome (1)
Azacitidine (1) · Bortezomib (1)
United States (2)
R01CA282411 (1)